Eli Lilly and Company (NYSE:LLY) is one of the most profitable NYSE stocks to buy right now. In a report released on December ...

Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also ...

Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as new therapies expand global market leadership.

Eli Lilly’s weight loss drugs have delivered blockbuster sales in recent quarters. The company is a leader in this market ...

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company ...

The first reveal of clinical data with Eli Lilly’s injectable triple receptor agonist for obesity suggests that the company could have a big winner on its hands if the drug makes it through to market.

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

The clinical trial showed this experimental medication to be much more effective than any existing GLP-1 drug. But that much ...

ACIP votes to change hep B vaccination for infants; positive results for retatrutide; Omisirge approved; counterfeit Ozempic seized by FDA; gene therapy ...

Important state and national stories, market and business news, sports and entertainment, delivered in quick-hit fashion ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Major stock indexes ended mixed Thursday, with the Dow Jones Industrial Average and S&P 500 closing at record highs but the ...